Menu Search
Equities

Read Gene SA

RDG:WSE

Read Gene SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)5.86
  • Today's Change0.02 / 0.34%
  • Shares traded2.24k
  • 1 Year change+97.97%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Read Gene SA had net income fall from a gain of 213.22k to a loss of 1.35m despite a 40.14% increase in revenues from 7.24m to 10.15m. An increase in the selling, general and administrative costs as a percentage of sales from 36.76% to 39.22% was a component in the falling net income despite rising revenues.
Gross margin92.67%
Net profit margin-8.63%
Operating margin-8.42%
Return on assets-8.40%
Return on equity-44.45%
Return on investment-8.56%
More ▼

Cash flow in PLNView more

In 2023, cash reserves at Read Gene SA fell by 5.51m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 820.82k for operations while cash used for investing totalled 4.29m.
Cash flow per share-0.0485
Price/Cash flow per share--
Book value per share0.1583
Tangible book value per share0.1538
More ▼

Balance sheet in PLNView more

Read Gene SA uses little or no debt in its capital structure.
Current ratio23.55
Quick ratio23.52
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.